With FDA approval in sight, why Aerie's keen on global strategy too

With U.S. Food and Drug Administration approval potentially just around the corner, Aerie Pharmaceuticals (Nasdaq: AERI) has its sights set on global strategy as well. Aerie – which is developing a pipeline of treatments for glaucoma and other eye diseases and is beefing up its research and development team locally – is also well on its way pursuing regulatory approval in both Europe and Japan moving forward. "The company’s success to date, both clinical ly and financially, is what is allowing…
Source: bizjournals.com Health Care:Biotechnology headlines - Category: Biotechnology Authors: Source Type: news